Haseena Cassim to HIV-1
This is a "connection" page, showing publications Haseena Cassim has written about HIV-1.
Connection Strength
0,275
-
Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial. Lancet HIV. 2025 Mar; 12(3):e201-e213.
Score: 0,134
-
Factors associated with unsuppressed viremia in women living with HIV on lifelong ART in the multi-country US-PEPFAR PROMOTE study: A cross-sectional analysis. PLoS One. 2019; 14(10):e0219415.
Score: 0,093
-
Characterizing HIV drug resistance in cases of vertical transmission in the VESTED randomized antiretroviral treatment trial. J Acquir Immune Defic Syndr. 2024 Aug; 96(4):385-392.
Score: 0,032
-
Pharmacokinetics, safety and antiviral activity of fosamprenavir/ritonavir-containing regimens in HIV-infected children aged 4 weeks to 2 years-48-week study data. Pediatr Infect Dis J. 2014 Jan; 33(1):57-62.
Score: 0,016